Non-proportional hazards in immuno-oncology: Is an old perspective needed?

@article{Magirr2020NonproportionalHI,
  title={Non-proportional hazards in immuno-oncology: Is an old perspective needed?},
  author={Dominic Magirr},
  journal={Pharmaceutical statistics},
  year={2020}
}
  • D. Magirr
  • Published 9 July 2020
  • Mathematics, Medicine
  • Pharmaceutical statistics
A fundamental concept in two-arm non-parametric survival analysis is the comparison of observed versus expected numbers of events on one of the treatment arms (the choice of which arm is arbitrary), where the expectation is taken assuming that the true survival curves in the two arms are identical. This concept is at the heart of the counting-process theory that provides a rigorous basis for methods such as the log-rank test. It is natural, therefore, to maintain this perspective when extending… Expand

Figures and Tables from this paper

A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching
TLDR
A modified weighted log-rank test (mWLR) that aims at balancing these factors by down-weighting events occurring when many patients have switched treatment by predicting the hazard ratio function and using it to compute the weights of the mWLR. Expand
DESIGNING GROUP SEQUENTIAL CLINICAL TRIALS WHEN A DELAYED EFFECT IS ANTICIPATED: A PRACTICAL GUIDANCE
A common feature of many recent trials evaluating the effects of immunotherapy on survival is that non-proportional hazards can be anticipated at the design stage. This raises the possibility to useExpand
Window mean survival time.
TLDR
This work proposes a class of alternative estimates and tests to restricted mean survival time (RMST) which improves power in numerous survival scenarios while maintaining a level of interpretability, unlike weighted rank tests (WRTs). Expand
The Strong Null Hypothesis and the MaxCombo Test: Comment on “Robust Design and Analysis of Clinical Trials with Nonproportional Hazards: A Straw Man Guidance form a Cross-Pharma Working Group.”
TLDR
A “straw-man guidance” on the design and analysis of clinical trials with non-proportional hazards and a proposal to replace the log-ra... Expand
Design and Analysis of group-sequential clinical trials based on a modestly-weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance
A common feature of many recent trials evaluating the effects of immunotherapy on survival is that non-proportional hazards can be anticipated at the design stage. This raises the possibility to useExpand
Quantifying treatment differences in confirmatory trials under non-proportional hazards
  • J. L. Jiménez
  • Computer Science, Medicine
  • Journal of Applied Statistics
  • 2020
TLDR
Results show that, under non-proportional hazards, the hazard ratio and weighted hazard ratio have no straightforward clinical interpretation whereas the RMST ratio can be interpreted regardless of the proportional hazards assumption. Expand

References

SHOWING 1-10 OF 42 REFERENCES
Statistical and practical considerations in designing of immuno-oncology trials
TLDR
It is shown that the weighted log-rank test, using the Fleming-Harrington class of weights, can be used as supportive analysis to better reflect the impact of a delayed effect and possible long-term benefit in a subset of the overall population. Expand
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.
  • H. Uno, B. Claggett, +13 authors Lee-Jen Wei
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
TLDR
Critical concerns regarding this conventional practice of quantifying the underlying differences between groups with respect to a time-to-event end point are summarized and various well-known alternatives are discussed. Expand
Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis
TLDR
In the absence of prior knowledge regarding the underlying or non-PH patterns, the MaxCombo test is relatively robust across patterns, and multiple measures of the treatment effect should be prespecified as sensitivity analyses to describe the totality of the data. Expand
Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology
TLDR
The required tools in a software package are provided, allowing to model data generating processes under complex non‐proportional hazard scenarios, to simulate data from these models and to perform the weighted logrank tests. Expand
Comparison of survival distributions in clinical trials: A practical guidance
TLDR
It is shown that versatile tests, while achieving robustness to departures from proportional hazards, may lose interpretation of directionality (superiority or inferiority) and can only be seen to test departures from equality. Expand
Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group
TLDR
Design and analysis considerations based on a combination test under different non-proportional hazard types and a straw man proposal for practitioners are provided. Expand
Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?
  • B. Freidlin, E. Korn
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2019
TLDR
A caution is offered about some of these methods’ limitations in translating statistical evidence into clinical evidence, both for formal treatment-effect hypothesis testing and for estimation, when used for the primary analysis. Expand
Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations.
TLDR
The relative efficiency of the hazard ratio and t-MST tests with respect to the statistical power under various PH and non-PH models theoretically and empirically is assessed. Expand
Does Cox analysis of a randomized survival study yield a causal treatment effect?
TLDR
While the Cox model may be used as a basis for valid tests of the null hypotheses of no treatment effect if robust variance estimates are used, modeling frameworks more compatible with causal reasoning may be preferrable in general for estimation. Expand
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
TLDR
It is concluded that the hazard ratio cannot be recommended as a general measure of the treatment effect in a randomized controlled trial, nor is it always appropriate when designing a trial. Expand
...
1
2
3
4
5
...